Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Boston Scientific Corporation (NYSE:BSX) delivered a first-quarter miss in April and adjusted its 2019 guidance.
The stock holds several catalysts this year, including the FDA paclitaxel panel, a pipeline update at the company’s analyst meeting in June and the closing of the BTG acquisition, according to BMO Capital Markets.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Analyst
Joanne Wuensch maintained an Outperform rating on Boston Scientific and raised the price target from $44 to $46.
The Thesis
Boston Scientific’s shares have been under pressure due to paclitaxel-related concerns and the company’s first-quarter miss, resulting in an attractive entry point, Wuensch said in a Thursday note. (See her track record here.)
Boston Scientific has a rich pipeline, the analyst said. The Exalt-D single-use duodenoscope is expected to be launched by the end of the year, while the company’s next-gen Watchman FLX will be available in Europe soon, she said, adding that reimbursement approval for the Watchman is expected in the third quarter in Japan.
Additional upcoming catalysts include the MRI labeling for Vercise DBS with Directional Leads, expected in the back half of this year; the global launch of the Lotus TAVR valve; and the enrollment of Acurate neo2 for the U.S. IDE and a launch in Europe in mid-2019, Wuensch said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Boston Scientific is expected to provide an update during its June 26 analyst meeting.
The FDA’s Circulatory System Devices Panel is scheduled to meet June 19-20 for paclitaxel-related discussions and to make recommendations, the analyst said, adding that she expects this meeting to be a catalyst for the medical device maker.
The company stands out among its peers with high-single-digit organic revenue growth, operating leverage and double-digit EPS, according to BMO.
Price Action
Boston Scientific shares were up 0.76 percent at $38.39 at the time of publication Thursday.
Related Links:
Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
Analysts Shrug Off Softness In Edwards Lifesciences' Heart Value Replacement System
Photo courtesy of Boston Scientific.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.